anti-CD40L (human) mAb (rec.) (blocking) (hu5c8) (preservative free)
| Code | Size | Price |
|---|
| AG-27B-6002PF-C100 | 100 ug | £300.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Target Species:
- Canine (dog)
- Human
Applications:
- Fluorescence-activated cell sorting (FACS)
- Functional Study
- Western Blot (WB)
Shipping:
-20°C
Storage:
Short Term: 4°C Long Term: -20°C
Further Information
Alternate Names/Synonyms:
CD40 Ligand; CD154; Tumor Necrosis Factor Ligand Superfamily Member 5;TNFSF5; Gp39; TRAP
Concentration:
1mg/ml
EClass:
32160000
Endotoxin:
<0.001EU/µg
Form (Short):
liquid
Formulation:
Liquid. In PBS.
Handling Advice:
Avoid freeze/thaw cycles.
Immunogen:
Recombinant human CD40L.
Labels - Conjugates:
Preservative Free
Long Description:
Recombinant Antibody. Recognizes and binds human CD40L with an IC50 of 0.845µg/ml. Cross-reacts with canine CD40L. Species cross-reactivity: Dog, Human. Clone: hu5c8. Isotype: Human IgG1kappa. Applications: FACS, FUNC, FUNC (Blocking), WB. Host: . Liquid. In PBS. CD40 Ligand (CD40L), renamed TNFSF5 but now also known as CD154, TRAP and gp39, is a 34-39kDa type II transmembrane glycoprotein, that belongs to the TNF superfamily, and a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. CD40L binds to CD40, which is essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development and germinal center formation. CD40 is constitutively expressed by antigen presenting cells, including dendritic cells, B cells and macrophages. Consistent with its widespread expression on normal cells, CD40 is also expressed on a wide range of tumor cells. CD40L levels are increased in serum and in inflamed tissues of patients with autoimmune diseases.
NCBI, Uniprot Number:
P29965
Other data:
This antibody is a biosimilar called Ruplizumab (Antova; BG9588) and originally developed by Biogen. Ruplizumab is a CD40 ligand blocker designed for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis, but withdrawn from clinical trials due to side effects.
Package Type:
Plastic Vial
Product Description:
CD40 Ligand (CD40L), renamed TNFSF5 but now also known as CD154, TRAP and gp39, is a 34-39kDa type II transmembrane glycoprotein, that belongs to the TNF superfamily, and a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. CD40L binds to CD40, which is essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development and germinal center formation. CD40 is constitutively expressed by antigen presenting cells, including dendritic cells, B cells and macrophages. Consistent with its widespread expression on normal cells, CD40 is also expressed on a wide range of tumor cells. CD40L levels are increased in serum and in inflamed tissues of patients with autoimmune diseases.
Purity:
>95% (SDS-PAGE)
Specificity:
Recognizes and binds human CD40L with an IC50 of 0.845µg/ml. Cross-reacts with canine CD40L.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C.
References
Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys: J.V Gobburu, et al.; JPET 286, 925 (1998) | Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates: A.D. Kirk, et al.; Nat. Med. 5, 686 (1999) | Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154: N.S. Kenyon, et al.; PNAS 96, 8132 (1999) | Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154: N.S. Kenyon, et al.; Diabetes 48, 1473 (1999) | Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody: R.N. Pierson, et al.; Transplantation 68, 1800 (1999) | Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody: M. Karpusas, et al.; Structure 9, 321 (2001) | Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients: C.S. Cho, et al.; Transplantation 72, 587 (2001) | Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates: E.A. Elster, et al.; Transplantation 72, 1473 (2001) | The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus: W. Huang, et al.; Arthr. Rheum. 46, 1554 (2002) | Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates: H. Xu, et al.; Transplantation 74, 940 (2002) | A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis: D.T. Boumpas, et al.; Arthr. Rheum. 48, 719 (2003) | Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions: A.C. Grammer, et al.; J. Clin. Invest. 112, 1506 (2003) | Human CD34(+) blood cells induce T-cell unresponsiveness to specific alloantigens only under costimulatory blockade: M. Arpinati, et al.; Exp. Hematol. 31, 31 (2003) | CD154 blockade and donor-specific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1-Gy total body irradiation: C. Jochum, et al.; Biol. Blood Marrow. Transplant. 13, 164 (2007) | Enhancement of T cell activation by immobilized hu5C8 (anti-CD40L) monoclonal antibody: M. Arpinati, et al.; Eur. J. Haematol. 80, 322 (2008) | Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig: S.S. Graves, et al.; Transplantation 88, 317 (2009)